Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, provided today the following technological update. The LIGHT system has been designed to electronically control the..
Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that further to the Company’s announcement of 3 April 2018, the Company has received from..
Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announced today that is has signed a lease with the UK Government’s Science and Technology Facilities..
Advanced Oncotherapy Plc (LON:AVO) is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology developed originally at the world-renowned CERN. Major technical milestones were achieved in..
Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announced today that in relation to the announcement dated 7 December 2017 and following the passing..
Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it remains on schedule with the development of the first LIGHT system, as per..
Advanced Oncotherapy Plc (LON:AVO) is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology originally developed at the world-renowned CERN. Major milestones have been achieved in..
Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has signed an exclusive distribution agreement (the “Distribution Agreement”) with Yantai CIPU Medical..
Advanced Oncotherapy Plc (LON:AVO) Senior Vice-President in charge of Client Services, Simon Lee, discusses the installation and services related to LIGHT, the company’s proton therapy system. Q: Simon, what is..
Advanced Oncotherapy PLC (LON:AVO) is the topic of conversation when Hardman and Co’s Analyst Dr Martin Hall caught up with DirectorsTalk for an exclusive interview Q1: Advanced Oncotherapy released..
Advanced Oncotherapy plc (LON:AVO), Executive Chairman, Mike Sinclair provides an insight into his background in healthcare, his vision for AVO and the opportunity the Company has to transform the global..
Advanced Oncotherapy Plc (LON:AVO) is the topic of conversation when Hardman & Co Analyst Dr Martin Hall caught up with DirectorsTalk. Martin shares his thoughts on the latest interims, explains..
Advanced Oncotherapy Plc (LON:AVO) is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology originally developed at the world renowned CERN. The company is entering an..
Advanced Oncotherapy Plc (LON:AVO), the developer of a next generation proton therapy system for cancer treatment, announced today its unaudited results for the six months ended 30 June 2017 and..
Advanced Oncotherapy plc (LON:AVO) Chief Operating Officer Ed Lee talks to DirectorsTalk about his background, what that experience brings to AVO and how that knowledge can translate into shareholder value...
Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announced today that it remains on schedule with the development of the first LIGHT system, with..
Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announced today the completion of a further technological milestone in the manufacture of its first LIGHT..
Advanced Oncotherapy PLC (LON:AVO) Chief Executive Officer, Nicolas Serandour, talks to DirectorsTalk to discuss the opportunities ahead, the challenges AVO has faced, what’s been done to overcome those obstacles and..
Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announced today the release of a short video providing an update on the facility at Harley..
Advanced Oncotherapy Plc (LON:AVO), the developer of next generation proton therapy systems for cancer treatment, announced today it’s audited results for the year ended 31 December 2016, another year of..
